Skip to main content

Table 3 KI benefit response after the second treatment cycle (worst case scenario)

From: Second-line Treatment of Stage III/IV Non-Small-Cell Lung Cancer (NSCLC) with pemetrexed in routine clinical practice: Evaluation of performance status and health-related quality of life

 

KI benefit response a All patients (N = 521) n (%) of patients [95% CI]

Responders overall

302 (58.0) [53.6; 62.2]

   0% improvement of KI, but maintained ≥ 80%

151 (29.0)

   10% improvement of KI

97 (18.6)

   20% improvement of KI

7 ( 1.3)

   30% improvement of KI

2 ( 0.4)

   Worsening of KI, but still maintained ≥ 80%

45 ( 8.6)

Non-responders, overall

219 (42.0) [37.8; 46.4]

   0% worsening of KI, but maintained < 80%

67 (12.9)

   Deterioration of KI, developed KI < 80%

102 (19.6)

   Missing data b

50 ( 9.6)

  1. CI confidence interval, KI Karnofsky Index, N = total number of patients, n = number of patients
  2. a) Defined as improvement in KI of at least 10% (absolute) or maintenance/achievement of an absolute KI of at least 80%
  3. b) Patients who discontinued prior to the end of the second treatment cycle or who had missing KI data were considered as non-responders (worst case scenario)